Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome

Next Previous
X
Search
Trial Profile

A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Fragile X syndrome
  • Focus Proof of concept; Therapeutic Use
  • Acronyms GNX
  • Sponsors Marinus Pharmaceuticals

    • Most Recent Events

    • 28 Apr 2017 Status changed from active, no longer recruiting to completed,according to the results published in Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results assessing safety and efficacy presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Jun 2016 According to a Marinus Pharmaceuticals media release, the company in collaboration with University of California (UC) Davis and Antwerp University Hospital, is continuing to analyze the data and planning to submit the data in its entirety for presentation at the National Fragile X Conference in July.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top